Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Macrogenics (MGNX)

Macrogenics (MGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 102,480
  • Shares Outstanding, K 63,259
  • Annual Sales, $ 149,960 K
  • Annual Income, $ -66,970 K
  • EBIT $ -114 M
  • EBITDA $ -109 M
  • 60-Month Beta 1.52
  • Price/Sales 0.67
  • Price/Cash Flow N/A
  • Price/Book 1.51

Options Overview Details

View History
  • Implied Volatility 221.80% (-0.12%)
  • Historical Volatility 74.70%
  • IV Percentile 65%
  • IV Rank 28.47%
  • IV High 704.13% on 04/03/25
  • IV Low 29.83% on 04/04/25
  • Expected Move (DTE 21) 0.5440 (33.79%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 53
  • Volume Avg (30-Day) 83
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 2,970
  • Open Int (30-Day) 4,681
  • Expected Range 1.0660 to 2.1540

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.42
  • Number of Estimates 4
  • High Estimate -0.06
  • Low Estimate -0.70
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -68.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3200 +21.97%
on 12/17/25
1.6900 -4.73%
on 12/23/25
+0.1300 (+8.78%)
since 11/26/25
3-Month
1.2900 +24.81%
on 11/07/25
2.1500 -25.12%
on 10/22/25
-0.1200 (-6.94%)
since 09/26/25
52-Week
0.9900 +62.63%
on 04/07/25
3.6000 -55.28%
on 01/06/25
-1.6500 (-50.61%)
since 12/26/24

Most Recent Stories

More News
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference

ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 1.6100 (-0.62%)
MacroGenics: Q3 Earnings Snapshot

MacroGenics: Q3 Earnings Snapshot

MGNX : 1.6100 (-0.62%)
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress

Achieved additional $75 million in partnering proceeds from Sanofi and Gilead Granted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platform...

MGNX : 1.6100 (-0.62%)
MacroGenics to Participate in the Stifel 2025 Healthcare Conference

ROCKVILLE, MD, Nov. 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 1.6100 (-0.62%)
MacroGenics to Present at H.C. Wainwright 27th Annual Global Investment Conference

ROCKVILLE, MD, Sept. 02, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 1.6100 (-0.62%)
Cancer Treatment Revolution Drives $903B Market as New Therapies Gain Momentum

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Researchers at Moffitt Cancer Center have uncovered a promising new therapeutic strategy that could potentially...

ONCY : 0.9520 (-1.86%)
BCT.TO : 11.24 (+5.44%)
MGNX : 1.6100 (-0.62%)
KPTI : 7.44 (-0.40%)
BCTX : 7.74 (-4.33%)
CTOR : 1.1300 (-1.31%)
MacroGenics: Q2 Earnings Snapshot

MacroGenics: Q2 Earnings Snapshot

MGNX : 1.6100 (-0.62%)
MacroGenics Reports Second Quarter 2025 Financial Results and Highlights Key Strategic Priorities

Newly-appointed President and CEO, Eric Risser, outlines strategic priorities for 2025 and 2026 Received $70 million upfront cash payment from Sagard Healthcare Partners under a royalty purchase agreement...

MGNX : 1.6100 (-0.62%)
MacroGenics Appoints Eric Risser as President and Chief Executive Officer

ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer,...

MGNX : 1.6100 (-0.62%)
Investors Turn to Cancer Breakthroughs as Federal Funding Faces Deep Cuts

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – With cancer cases rising and treatment costs hitting new highs, the private sector is under growing pressure...

ONCY : 0.9520 (-1.86%)
MGNX : 1.6100 (-0.62%)
AGEN : 3.31 (-1.19%)
TIL : 11.31 (-1.31%)
ONC.TO : 1.42 (+2.16%)
CATX : 2.88 (+2.49%)

Business Summary

MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics...

See More

Key Turning Points

3rd Resistance Point 1.7233
2nd Resistance Point 1.6767
1st Resistance Point 1.6483
Last Price 1.6100
1st Support Level 1.5733
2nd Support Level 1.5267
3rd Support Level 1.4983

See More

52-Week High 3.6000
Fibonacci 61.8% 2.6030
Fibonacci 50% 2.2950
Fibonacci 38.2% 1.9870
Last Price 1.6100
52-Week Low 0.9900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar